Clinical Trial: Evaluating the Safety and Efficacy of Rupatadine in the Treatment of Nonalcoholic Fatty Liver Disease Patients.

U.S., Oct. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07900100) titled 'Evaluating the Safety and Efficacy of Rupatadine in the Treatment of Nonalcoholic Fatty Liver Disease Patients.' on Oct. 21.

Brief Summary: NAFLD is characterized by excessive hepatic fat accumulation without other recognized causes of increased fat content (e.g., alcohol, virus, drugs, and autoimmunity). According to the Clinical Practice Guidelines of the European Association for the Study of the Liver, the diagnosis of NAFLD requires the exclusion of daily alcohol consumption >30 g for men and >20 g for women

Study Start Date: Oct. 25

Study Type: INTERVENTIONAL

Condition: NAFLD (Nonalcoholic Fatty Liver Disease)

Intervention...